ダパグリフロジンとロスヴァスタチンの薬物相互作用による重度のラブドミオリシス: 症例報告
Anaghashree Udayashankar1, Topoti Mukherjee1, Kristin George1
1Department of Nephrology and Renal Transplantation, Aster Whitefield, Bengaluru, India.
Indian journal of nephrology
|September 2, 2025
まとめ
ナトリウム・グルコース・コトランスポーター2阻害剤 (SGLT2i) とスタチンを併用すると,ラブドミオリスのリスクが増加する可能性があります. この症例は2型糖尿病患者における この薬剤の組み合わせによる 重度の急性腎臓損傷を強調しています
科学分野:
- 薬理学について
- 腎臓科
- 内分泌学
背景:
- 2型糖尿病における心血管疾患のリスクを減らすために,ナトリウム・グルコース・コトランスポーター-2阻害剤 (SGLT2i) とスタチンは広く処方されています.
- SGLT2iとスタチンの間の潜在的な薬物相互作用,特に筋毒性については,完全に解明されていません.
関連する概念動画
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Pharmacokinetics: Drug–Drug Interactions
813
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
813
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
695
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
695
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
379
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Drug toxicity: Drug–Drug Interaction
423
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
423
Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K


